It has also been reported that in a head and neck cancer model, increased resistance to cetuximab is associated with increased PD-1 and Tim-3 expression on tumor-infiltrating lymphocytes41, further suggesting the need for a multi-dimensional approach to cancer treatment. Here, HAVCR2 is linked to head and neck cancer.